News-Medical.Net on MSN

Novel antisense oligonucleotide shows promise against aggressive pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...
FierceBiotech

GSK pays $17.5M for CAMP4 regulatory RNA deal

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications. CAMP4 ...
Monthly Prescribing Reference

Calpain-2 Targeting Antisense Oligonucleotide Fast Tracked for ALS

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...
Hosted on MSN

PLX: Secarna’s antisense oligonucleotide discovery collaboration

Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO) therapies using Secarna’s ...
BioWorld

Preclinical profiling of Splisense’s inhaled antisense oligonucleotide

Researchers from Splisense Ltd. and affiliated organizations recently reported preclinical data for SPL-84, an inhaled antisense oligonucleotide drug candidate being developed for the treatment of ...
BioWorld

Antisense oligonucleotide targeting nicotinamide N-methyltransferase as a potential cancer therapy

Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs) ...